Breast Cancer, Version 4.2023 Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Doreen Agnese, H. Allison Kimberly, Bethany Anderson, Harold J. Burstein, Helen Chew, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn LeitchJanice Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Bryan Schneider, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, Mei Wei Md, Kari B. Wisinski, Jessica S. Young, Kay Yeung, Mary A. Dwyer, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates specific to systemic therapy recommendations for patients with stage IV (M1) disease.

Original languageEnglish
Pages (from-to)594-608
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume21
Issue number6
DOIs
StatePublished - Jun 2023

Fingerprint

Dive into the research topics of 'Breast Cancer, Version 4.2023 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this